Researchers have engineered a minimal type I-F2 CRISPR-Cas system capable of transcriptional activation and base editing in human cells. This...

Paris-headquartered Eligo Bioscience has achieved a major breakthrough in microbiome editing. In an article published moments ago in Nature, the...

Based on an evolved bacterial adenosine deaminase, DECOR represents a significant advancement in RNA editing technology by providing a more precise,...

In a new breakthrough, researchers have achieved significant advances in gene editing of lung stem cells, demonstrating the potential for durable...

Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

Verve Therapeutics has announced the first human proof-of-concept data demonstrating durable reductions in cholesterol for its in vivo base-editing...